Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

SAN DIEGO, May 2, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the first quarter ended March 31, 2013.

During the first quarter of 2013, Cadence reported net product revenue from sales of OFIRMEV® (acetaminophen) injection of $23.6 million, which includes the one-time recognition of $2.6 million in deferred revenue on previously shipped product. Consistent with other companies with products at this stage of commercialization, and based upon its determination it had obtained sufficient product return history to reasonably estimate future wholesaler returns, beginning on January 1, 2013, the company began to recognize revenue at the time that the product is sold to a wholesaler.

Excluding the recognition of $2.6 million in previously deferred revenue, net product revenue for the first quarter of 2013 was $21.0 million, which represents an increase of more than 160% from the $8.0 million in net product revenue recognized for the first quarter of 2012, and an increase of 23% from the $17.1 million recognized for the fourth quarter of 2012.

Highlights for the first quarter of 2013 included:

  • The gross margin on sales of OFIRMEV was 65% for the first quarter of 2013, as compared to 47% for the first quarter of 2012.
  • As of March 31, 2013, the company had over 4,000 unique customer accounts, an increase of nearly 50% from the first quarter of 2012.
  • The average order size by end-user customers increased 28% during the first quarter of 2013 as compared to the first quarter of 2012.
  • On March 12, 2013, the company announced that the Department of Veterans Affairs added OFIRMEV to the VA Natio
    '/>"/>

  • SOURCE Cadence Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
    2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
    3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
    4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
    5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
    6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
    7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
    8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
    9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
    10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
    11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... BioLight Life Sciences Investments ... a firm that invests in, manages and commercializes ... today that presentations highlighting its IOPtiMate™ system for ... the Ophthalmology Futures European Forum and the XXXIII ... Refractive Surgeons ("ESCRS"), both taking place in the ...
    (Date:9/2/2015)... ... ... Temarry Recycling's new $100,000 waste to energy capital project ... to contribute to the sustainability of our natural resources. , Waste to Energy ... operating at their Mexico facility, Recicladora Temarry, for the last 7 years. While ...
    (Date:9/1/2015)... 2015 The American Brain Tumor Association (ABTA) ... Discovery Research Grant program. LOIs are due no later ... Discovery Grants are one-year, $50,000 grants that ... change current diagnostic or treatment paradigms for adults and ... research at its earliest stages, in the hopes that ...
    (Date:9/1/2015)... ... September 01, 2015 , ... AxioMx Inc. ... the National Institutes of Health (NIH) has awarded the company a Phase I ... NIH’s National Institute of Diabetes and Digestive and Kidney Diseases. AxioMx will use ...
    Breaking Biology Technology:Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 2AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 3
    ... Corp. (Nasdaq: KOOL ), a leading supplier of ... cells, said today that the FDA has agreed with its ... AXP disposable bagsets that it announced in November.At that time, ... result of any safety issues; the field action was a ...
    ... Va., Feb. 26 Insmed Inc. (Nasdaq: ... it will host a conference call on Wednesday, March ... results for the fourth quarter and year-end 2008. ... before the market opens on March 11th.To participate in ...
    ... launched its revolutionary Trusted LASIK Surgeons directory service and ... a resource for consumers seeking to improve their vision ... improve their chances of attaining 20-20 vision. What ... unique screening process ensuring that only those who are ...
    Cached Biology Technology:ThermoGenesis Says FDA Concurs with Plan for Previously Announced AXP(TM) Bagset Recall 2ThermoGenesis Says FDA Concurs with Plan for Previously Announced AXP(TM) Bagset Recall 3Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call 2Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 2Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 3Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 4Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 5Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 6Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 7Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 8
    (Date:8/26/2015)... , August 26, 2015 ... Four, and Five Factor), Application (Travel & Immigration, Government, ... - Global Forecast to 2020", published by MarketsandMarkets, Multi-Factor ... by 2020, growing at a CAGR of 17.7% between ... and 82 F igures spread through 169 ...
    (Date:8/20/2015)... 20, 2015   Sensory, Inc ., a ... user experience and security of consumer electronics through ... that its TrulySecure™ is the first ... be FIDO Certified™. The FIDO (Fast ... the FIDO UAF (Universal Authentication Framework) 1.0 specifications, ...
    (Date:8/17/2015)... OXFORD, Conn. , Aug. 17, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces its new sales campaign for Q4 2015. The ... winning marketing team consisting of Amplitude Marketing Group ( ... Amplitude Marketing Group is a leader in retail driven ...
    Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
    ... sensitive new genetic test can now detect a crippling disease ... to Virginia and north to Canada. Although it does not ... red tide, the disease can have a significant impact on ... harvests and commercial aquaculture operations. , QPX - for quahog ...
    ... future of the tropics unfolds, scientists must explain the ... increase and environmental changesAs human populations and their impacts ... many different ways. Forests are being cleared, burned, ... they are also being altered in insidious ways by ...
    ... me sad when an article that should have picture doesn't ... student's group in the iGEM competition , check it out! ... 'camera'. , Using Petri dishes full of genetically engineered ... of Texas at Austin and UCSF successfully created the first-ever ...
    Cached Biology News:New genetic test can detect clam disease 2Scientists must offer solutions for conserving tropical forests in a rapidly changing world 2Student scientists create living bacterial photographs 2Student scientists create living bacterial photographs 3
    ... Specificity: This antibody recognizes ... not cross-react with other related ... antibody with murine IRF7 protein ... analysis of the 293T cells ...
    Rabbit anti-phospho-EGFr (Tyr992) - Concentrate...
    Contains L-glutamine...
    ... biosynthesized by the 11(R)-LOs of the ... fresh water hydra, H. vulgaris. The ... oocyte maturation and tentacle regeneration, respectively, ... produced when aspirin-treated recombinant COX-2 is ...
    Biology Products: